CD4 and primary cutaneous T-cell non-Hodgkin lymphoma: However, CD4 monoclonal antibody treatments against CTCL (e.g., zanolimumab) have shown high response rates in patients with MF but are less effective in patients with SS, indicating significant differences in response to therapy across CTCL subtypes [27].